AVTX Earnings Date: Nov 5, 2026 (Estimated) — Avalo Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is AVTX's next earnings date?
Avalo Therapeutics, Inc. (AVTX) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.59.
How did AVTX do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Avalo Therapeutics, Inc. posted EPS of -$0.83 versus the -$0.58 estimate, a miss of 31.8%. Revenue was $0. The stock's 1-day post-earnings move was -0.7%.
How much does AVTX stock move after earnings?
AVTX beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 2.1% (up or down) in the day after earnings.
About Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monoclonal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.58 | -0.83 | -31.75% | $0 | ❌ Miss | -0.74% | +3.77% | +0.85% |
| 2026-05-13 | Q1 2026 | -1.01 | -0.98 | +2.97% | $0 | ✅ Beat | -0.45% | -18.41% | -31.44% |
| 2026-03-23 | Q4 2025 | -1.51 | -0.48 | +68.21% | $59,000 | ✅ Beat | +0.60% | +3.50% | +6.48% |
| 2025-11-06 | Q3 2025 | -1.65 | -2.19 | -32.73% | $0 | ❌ Miss | -6.26% | -6.20% | +6.75% |
| 2025-08-07 | Q2 2025 | -1.46 | -1.92 | -31.51% | $0 | ❌ Miss | +0.48% | +9.21% | +39.59% |
| 2025-05-12 | Q1 2025 | -1.61 | -1.25 | +22.36% | $0 | ✅ Beat | -1.48% | -3.69% | +18.72% |
| 2025-03-20 | Q4 2024 | -1.39 | 1.72 | +223.74% | $192,000 | ✅ Beat | +2.88% | +4.63% | -44.81% |
| 2024-11-07 | Q3 2024 | -1.45 | -2.83 | -95.17% | $249,000 | ❌ Miss | -3.66% | +0.00% | -24.25% |
Showing last 8 quarters.